Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 101 UK neurodegenerative disease companies below.
Antisense oligonucleotide gene therapies for rare childhood leukodystrophies
SynaptixBio is a rare disease biotech company developing gene therapies for severe leukodystrophies and childhood neurodegenerative diseases, using antisense oligonucleotide…
AI-driven target identification and drug discovery from omics data
Intelligent OMICS is a biotechnology company applying artificial intelligence and machine learning to drug discovery and diagnostics. Its proprietary platform analyses…
Digital cognitive assessment and CNS clinical trial software platform
Cambridge Cognition provides digital cognitive assessment and clinical trial technology for central nervous system drug development. Its validated computerised tests measure…
Nanotechnology drug delivery platform for precision medicines
Nanomerics is a UK speciality pharmaceutical company developing precision medicines using its proprietary technology, a polymer nanotechnology platform that improves the…
Small molecule inhibitors targeting somatic expansion in neurodegeneration
LoQus23 Therapeutics is a biotechnology company developing oral small molecule inhibitors of DNA mismatch repair for the treatment of Huntington's disease and other triplet repeat…
Targeted protein degradation platform for neurodegenerative disease
TRIMTECH Therapeutics is a biotechnology company developing small-molecule degraders that selectively remove disease-causing protein aggregates while preserving the functional,…
RBC derived nanoparticles for RNA delivery to brain and immune cells
Crane Biosciences is a biotechnology company developing a non-immunogenic RNA delivery platform based on nanoparticles derived from red blood cell membranes. By using the body's…
Tunable covalent chemistry platform for neurodegenerative disease
Dunad Therapeutics is a drug discovery biotech developing small molecule therapies for neurodegenerative diseases including ALS, frontotemporal dementia, and Parkinson's disease.…
Stem cell-derived exosome platform for targeted drug delivery
ReNeuron is a biotechnology company developing a stem cell-derived exosome platform for targeted therapeutic delivery. Founded on over two decades of stem cell science, including…
Autophagy-enhancing small molecule drugs for neurodegeneration and rare disease
Samsara Therapeutics is a drug discovery company developing first-in-class small molecule therapeutics that restore autophagy, the cellular process of degrading and recycling…
Next-generation targeted protein degradation therapeutics
Amphista Therapeutics is a Cambridge-based biopharmaceutical company developing next-generation targeted protein degradation medicines. Its proprietary platform generates…
Preclinical DMPK, bioanalysis and toxicology CRO
Pharmidex is a UK contract research organisation providing preclinical drug discovery and development services across DMPK, bioanalysis, toxicology, histology and in vitro ADME.…